Polish Bioton To Acquire Local Insulin Producer

Poland’s Bioton plans to finalize the acquisition of the state’s 70% stake in the country’s leading insulin producer, Indar, by the end of June; enlarging Bioton’s stake in the company from the 29.3% to 99.3%. Indar reported about USD 17.8 mln revenues in 2006. The company has around a 65-70% share of the Ukrainian insulin market.